MD Anderson and Astex Pharmaceuticals announce strategic collaboration to accelerate clinical evaluation of therapies for patients with leukemia
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center and Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., based in Tokyo, Japan, today announce a strategic collaboration agreement aimed at accelerating the clinical evaluation of Astex's pipeline of products for patients with certain types of leukemia, including myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML). The collaboration will combine MD Anderson's clinical trials infrastructure and expertise with Astex's clinical pipeline p...
Source: EurekAlert! - Cancer - September 8, 2020 Category: Cancer & Oncology Source Type: news

INQOVI (decitabine and cedazuridine) Tablets, FDA Approved for Treatment of Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia, Available at Biologics by McKesson
CARY, N.C., Aug. 24, 2020 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Taiho Oncology, Inc. as a specialty pharmacy provider for INQOVI® (decitabine and cedazuridine) tablets for the treatment of adults with intermedia... (Source: McKesson News)
Source: McKesson News - August 24, 2020 Category: Information Technology Source Type: news

Identified gene mutations impact on the severity of a type of hematologic cancer
(Josep Carreras Leukaemia Research Institute) Researchers from Josep Carreras Leukemia Research Institute participate in an international study that confirms for the first time that mutation of the two TP53 gene's copies is associated with a worse prognosis in myelodysplastic syndromes, a group of blood cancers a more frequent in elderly population. The results of this study have been published in Nature Medicine journal and represent an advance in the diagnosis and treatment of this type of hematological cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 4, 2020 Category: Cancer & Oncology Source Type: news

Large international study pinpoints impact of TP53 gene mutations on blood cancer severity
(Memorial Sloan Kettering Cancer Center) A large international study led by researchers at Memorial Sloan Kettering has immediate clinical relevance for risk assessment and treatment of people with myelodysplastic syndrome and acute myeloid leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 3, 2020 Category: Cancer & Oncology Source Type: news

FDA Approves Oral Treatment for Myelodysplastic Syndrome
Title: FDA Approves Oral Treatment for Myelodysplastic SyndromeCategory: Health NewsCreated: 7/8/2020 12:00:00 AMLast Editorial Review: 7/9/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - July 9, 2020 Category: Cancer & Oncology Source Type: news

FDA Approves Oral Therapy for Myelodysplastic Syndromes, CMML FDA Approves Oral Therapy for Myelodysplastic Syndromes, CMML
The Food and Drug Administration has approved Inqovi (decitabine and cedazuridine tablets, Astex Pharmaceuticals) to treat adults with myelodysplastic syndromes or chronic myelomonocytic leukemia (CMML).FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 9, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Oral Treatment for Myelodysplastic Syndrome
WEDNESDAY, July 8, 2020 -- The U.S. Food and Drug Administration has approved Inqovi (decitabine and cedazuridine) tablets, an oral outpatient treatment option for patients with myelodysplastic syndromes and chronic myelomonocytic leukemia, the... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 8, 2020 Category: General Medicine Source Type: news

FDA Approves Inqovi (decitabine and cedazuridine) for Myelodysplastic Syndromes (MDS) including Chronic Myelomonocytic Leukemia (CMML)
Pleasanton, CA, Princeton, NJ, and Tokyo, Japan, July 7, 2020. Astex Pharmaceuticals, Inc.; Taiho Oncology, Inc.; and Otsuka Pharmaceutical Co., Ltd. today announce that the U.S. Food and Drug Administration (FDA) and Health Canada have approved... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 8, 2020 Category: Drugs & Pharmacology Source Type: news

FDA approves oral combination of decitabine and cedazuridine for myelodysplastic syndromes
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - July 7, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

New treatment target verification for myelodysplastic syndrome
(Kumamoto University) A Japanese research group analyzed the pathophysiology of myelodysplastic syndrome (MDS), a blood cancer that presents often in the elderly, and found the presence of transcription factor RUNX3, thereby revealing a cancer growth function for what had been considered be a tumor suppressor. Additional analyses of human MDS cells and model mice found an abnormal gene expression mechanism linked to the onset of cancer, and confirmed RUNX3 as a potential therapeutic target. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 8, 2020 Category: International Medicine & Public Health Source Type: news

SF3B1 Variant in MDS Found to Identify Distinct Disease Entities
An international working group of experts in myelodysplastic syndromes proposed the recognition of the SF3B1 variant as a distinct nosologic entity based on the presence of a non-inheritable genetic mutation that causes the disease. (Source: CancerNetwork)
Source: CancerNetwork - May 17, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

EU Panel OKs Glasdegib for AML & Luspatercept for MDS EU Panel OKs Glasdegib for AML & Luspatercept for MDS
Glasdegib has been recommended for approval in Europe for acute myeloid leukemia, and luspatercept has been recommended for anemia associated with myelodysplastic syndromes.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 1, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

EU Panel OKs Glasdegib for AML and Luspatercept for MDS EU Panel OKs Glasdegib for AML and Luspatercept for MDS
Glasdegib has been recommended for approval in Europe for acute myeloid leukemia, and luspatercept has been recommended for anemia associated with myelodysplastic syndromes.International Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 1, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

First Advance in MDS for Decade: Luspatercept for Anemia First Advance in MDS for Decade: Luspatercept for Anemia
Luspatercept is now approved for use in the treatment of anemia in patients with myelodysplastic syndromes (MDS).FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 6, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Luspatercept to Treat Anemia in Patients with Lower-Risk MDS
The FDA approved the first and only erythroid maturation agent for the treatment of anemia in patients with lower-risk myelodysplastic syndromes. (Source: CancerNetwork)
Source: CancerNetwork - April 6, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

FDA Approves Reblozyl (luspatercept-aamt) to Treat Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)
PRINCETON, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 3, 2020-- Bristol Myers Squibb (NYSE: BMY) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced the U.S. Food and Drug Administration (FDA) has... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 3, 2020 Category: Drugs & Pharmacology Source Type: news

Chelation Beneficial in Iron-overloaded Patients at Lower Risk of Myelodysplastic Syndromes Chelation Beneficial in Iron-overloaded Patients at Lower Risk of Myelodysplastic Syndromes
Iron chelation therapy (ICT) with deferasirox led to longer event-free survival in iron-overloaded patients at low-to-intermediate risk of myelodysplastic syndrome (MDS) in a phase 2 study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 25, 2020 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Iron Chelation Therapy Treats Iron Overload in MDS
MONDAY, March 23, 2020 -- Iron chelation therapy (ICT) seems beneficial for iron-overloaded patients with low- or intermediate-1-risk myelodysplastic syndromes (MDS), according to a study published online March 24 in the Annals of Internal... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 23, 2020 Category: Pharmaceuticals Source Type: news

Use of Post-HSCT Cyclophosphamide Improves Transplantation Outcomes for AML/MDS
Hematopoietic stem cell transplantation (HSCT) with prior use of checkpoint inhibitors was found to be feasible in patients with acute myeloid leukemia and/or myelodysplastic syndromes and the use of post-HSCT cyclophosphamide as graft-versus host disease prophylaxis improves outcomes. (Source: CancerNetwork)
Source: CancerNetwork - March 12, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia
The initiating mutations that contribute to cancer development are sometimes present in premalignant cells. Whether therapies targeting these mutations can eradicate premalignant cells is unclear. Acute myeloid leukemia (AML) is an attractive system for investigating the effect of preventative treatment because this disease is often preceded by a premalignant state (clonal hematopoiesis or myelodysplastic syndrome). In Npm1c/Dnmt3a mutant knock-in mice, a model of AML development, leukemia is preceded by a period of extended myeloid progenitor cell proliferation and self-renewal. We found that this self-renewal can be reve...
Source: ScienceNOW - January 30, 2020 Category: Science Authors: Uckelmann, H. J., Kim, S. M., Wong, E. M., Hatton, C., Giovinazzo, H., Gadrey, J. Y., Krivtsov, A. V., Rücker, F. G., Döhner, K., McGeehan, G. M., Levine, R. L., Bullinger, L., Vassiliou, G. S., Armstrong, S. A. Tags: Medicine, Diseases reports Source Type: news

Reducing Blood Cancer Patients' Need for Transfusions
January 21, 2020—(BRONX, NY)—A clinical trial has found the drug luspatercept significantly reduced the need for blood transfusions in people with lower-risk myelodysplastic syndromes (MDS), a group of bone marrow disorders that leave people with many defective blood cells and too few normal ones. Approval by the Food and Drug Administration (FDA) would make luspatercept the first new drug available to MDS patients in 12 years.Results of the phase 3 clinical trial were published online January 9 in the New England Journal of Medicine (NEJM). (Source: Einstein News)
Source: Einstein News - January 22, 2020 Category: Universities & Medical Training Source Type: news

Drug Reduces Need for Transfusions in Some Patients With Myelodysplastic Syndromes Drug Reduces Need for Transfusions in Some Patients With Myelodysplastic Syndromes
Therapy every 3 weeks with the drug luspatercept dramatically reduced the need for blood transfusions in a subset of patients with lower-risk myelodysplastic syndromes (MDS), according to results from the MEDALIST study reported in the Jan. 9 New England Journal of Medicine.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 10, 2020 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Luspatercept Mitigates Anemia in Lower - Risk Myelodysplastic Syndromes
Transfusion burden reduced in patients with lower - risk myelodysplastic syndromes with ring sideroblasts (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 9, 2020 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Journal, Source Type: news

Luspatercept Mitigates Anemia in Lower-Risk Myelodysplastic Syndromes
WEDNESDAY, Jan. 8, 2020 -- For patients with lower-risk myelodysplastic syndromes with ring sideroblasts who have been receiving regular red-cell transfusions, luspatercept reduces the severity of anemia compared with placebo, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 8, 2020 Category: Pharmaceuticals Source Type: news

Medicare Coverage of HCT Recommended for Older Adults With Myelodysplastic Syndrome Medicare Coverage of HCT Recommended for Older Adults With Myelodysplastic Syndrome
A study of hematopoietic stem cell transplantation (HCT) for adults with myelodysplastic syndrome (MDS) showed that patients 65 and older had comparable outcomes to those ages 55 to 64, leading the authors to recommend that the US Centers for Medicare and Medicaid Services cover HCT.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 24, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Research revises classification of acute myeloid leukemia & myelodysplastic syndrome
(St. Jude Children's Research Hospital) Findings presented as a late-breaking abstract at the American Society of Hematology annual meeting by St. Jude Children's Research Hospital showcase the power and potential of combining genomic and transcriptomic data. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 10, 2019 Category: Cancer & Oncology Source Type: news

Isavuconazole (ISAV) as Primary Anti-Fungal Prophylaxis (PAP) in Patients (pts) with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS): An Open-Label, Prospective Study
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - November 12, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Isavuconazole (ISAV) As Primary Anti-Fungal Prophylaxis in Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective Study
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 8, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Causative Organisms and Resistance Patterns of Infection in Patients with Myelodysplastic Syndrome (MDS): A 20 Year Retrospective Analysis
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 7, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Epidemiology of Visceral Mycoses in Patients with Acute Leukemia and Myelodysplastic Syndrome: Analyzing the National Autopsy Database in Japan
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 7, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Pulmonary Infections in Patients with Myelodysplastic Syndromes Receiving Azacytidine Treatment
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 5, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

$5M grant to help Wash U research blood disorder therapies
The Washington University School of Medicine has received a $5 million grant from the Edward P. Evans Foundation to create a new center that will research rare blood disorders. The center will focus on a specific set of disorders, called myelodysplastic syndromes (MDS), which prohibits the body from creating enough healthy blood cells, according to a release. Dr. Matthew Walter will lead the center. Officials said MDS is hard to detect, with patients suffering from fat igue and shortness of breath.… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 12, 2019 Category: Biotechnology Authors: Vince Brennan Source Type: news

Couple Settles With Last Defendant In Benzene Suit On Eve Of Trial
OAKLAND, Calif. - A law firm representing a couple claiming that the man's exposure to benzene-containing products while working as an automobile mechanic caused him to develop myelodysplastic syndrome (MDS) announced July 1 that they had reached a settlement in California state court with the last defendant in the action on the eve of trial, bringing the total settlement amount to $6.3 million (Jimmy H. Thomas, et al. v. AZKO Nobel Coatings Inc., et al., No. RG-17-882514, Calif. Super., Alameda Co.). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - July 10, 2019 Category: Medical Law Source Type: news

Study to Evaluate the Safety and Efficacy of the Combination Therapy of Ibrexafungerp (SCY-078) With Voriconazole in Patients With Invasive Pulmonary Aspergillosis (SCYNERGIA)
This is a multicenter, randomized, double-blind, two-arm study to evaluate the safety, tolerability, efficacy and PK of the combination therapy of SCY-078 plus voriconazole compared to those of voriconazole monotherapy in male and female subjects 18 years of age and older with a hematological malignancy (HM) or a myelodysplastic syndrome or aplastic anemia or hematopoietic cell transplantation (HCT) and a probable or proven invasive pulmonary aspergillosis based on EORTCMSG criteria. In addition, all subjects must be positive ( ≥0.5) for serum GMI. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - July 3, 2019 Category: Respiratory Medicine Authors: GAtherton Source Type: news

Boy, 11, who has a rare blood cancer has been told there is nothing more doctors can do
Oliver Brown, from Devon, was told by doctors he had myelodysplastic syndrome when he was eight years old. At the time, doctors said he was the only boy in the country with the disease. (Source: the Mail online | Health)
Source: the Mail online | Health - June 25, 2019 Category: Consumer Health News Source Type: news

Transfusion Dose Density Affects Myelodysplastic Syndrome Survival
Negative effect of transfusion treatment on PFS occurs at density less than 3 units/16 weeks (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 24, 2019 Category: Cancer & Oncology Tags: Oncology, Journal, Source Type: news

Transfusion Dose Density Affects Myelodysplastic Syndrome Survival
MONDAY, June 24, 2019 -- Transfusion dose density is an independent prognostic factor for progression-free survival (PFS) in patients with myelodysplastic syndromes treated with red blood cell transfusions (RBCTs), according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 24, 2019 Category: Pharmaceuticals Source Type: news

Celgene Corporation and Acceleron Pharma Announce U.S. FDA Accepts Luspatercept Biologics License Application in Myelodysplastic Syndromes and Beta-Thalassemia
SUMMIT, N.J.& CAMBRIDGE, Mass.June 04, 2019 --(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted Celgene’s Biologics... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - June 4, 2019 Category: Drugs & Pharmacology Source Type: news

Lenalidomid Approved by FDA for Follicular and Marginal Zone Lymphoma
This thalidomide analogue is also indicated for multiple myeloma and myelodysplastic syndromes. (Source: CancerNetwork)
Source: CancerNetwork - May 28, 2019 Category: Cancer & Oncology Authors: Drew Boxler Source Type: news

Lenalidomide Approved by FDA for Follicular and Marginal Zone Lymphoma
This thalidomide analogue is also indicated for multiple myeloma and myelodysplastic syndromes. (Source: CancerNetwork)
Source: CancerNetwork - May 28, 2019 Category: Cancer & Oncology Authors: Drew Boxler Source Type: news

Newtown biopharm firm could reap $50M from Chinese licensing deal
Onconova Therapeutics Inc. could receive more than $50 million under a licensing deal it signed Monday for its lead experimental cancer therapy. HanX Biopharmaceuticals acquired the rights in Greater China to rigosertib, a new drug candidate Bucks County-based Onconova is developing initially as a treatment for patients at higher risks for developing myelodysplastic syndromes of MDA. MDS is a type of cancer that can occur when the blood-fo rming cells in bone marrow become abnormal. Under the… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 13, 2019 Category: Biotechnology Authors: John George Source Type: news

Aprea Therapeutics Receives FDA Fast Track Designation and Orphan Drug Designation for APR-246 for the Treatment of Myelodysplastic Syndromes (MDS)
BOSTON and STOCKHOLM, April 16, 2019 -- (Healthcare Sales & Marketing Network) -- Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, today announ... Biopharmaceuticals, Oncology, FDA Aprea Therapeutics, p53, myelodysplastic syndromes (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 16, 2019 Category: Pharmaceuticals Source Type: news

Aprea Therapeutics Adds New Investor to Series C Financing
Janus Henderson Investors joins Investor Group BOSTON and STOCKHOLM, Feb. 27, 2019 -- (Healthcare Sales & Marketing Network) -- Aprea Therapeutics, a clinical-stage biotechnology company developing novel anticancer therapies targeting the p53 tumor sup... Biopharmaceuticals, Oncology, Venture Capital Aprea Therapeutics, p53, myelodysplastic syndromes (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 27, 2019 Category: Pharmaceuticals Source Type: news

Does Chemotherapy Increase the Risks of Myelodysplastic Syndrome and Acute Myeloid Leukemia?
The study, published in JAMA Oncology, examined whether treatment of 22 solid tumor types was associated with two therapy-related conditions. (Source: CancerNetwork)
Source: CancerNetwork - February 7, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news

Myelodysplastic Syndrome/AML Risk Increased After Chemo
Since 2000, risks for therapy - related myelodysplastic syndrome, AML up after chemo for solid cancers (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 4, 2019 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Journal, Source Type: news

Myelodysplastic Syndrome/AML Risk Increased After Chemo
FRIDAY, Jan. 4, 2019 -- The risks for therapy-related myelodysplastic syndrome or acute myeloid leukemia (tMDS/AML) are elevated after chemotherapy use for solid tumors, according to a study published online Dec. 20 in JAMA Oncology. Lindsay M.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 4, 2019 Category: Pharmaceuticals Source Type: news

Study finds elevated risk of rare blood cancers after chemotherapy for most solid tumors
(NIH/National Cancer Institute) Findings from a new study by researchers at the National Cancer Institute (NCI) show that patients treated with chemotherapy for most solid tumors during 2000-2014 experienced an increased risk of therapy-related myelodysplastic syndrome/acute myeloid leukemia (tMDS/AML). The study was published December 20, 2018, in JAMA Oncology. NCI is part of the National Institutes of Health. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 20, 2018 Category: Cancer & Oncology Source Type: news

Identifying Molecular Markers of Relapse in Myelodysplastic Syndrome
In this month's installment ofAsk the PI,ONCOLOGY spoke with two authors of the study, Meagan A. Jacoby, MD, PhD, and Matthew Walter, MD, about their findings and what they might mean for practicing oncologists. (Source: CancerNetwork)
Source: CancerNetwork - December 17, 2018 Category: Cancer & Oncology Authors: Meagan A. Jacoby, MD, PhD, Matthew Walter, MD Source Type: news

Can Azacitidine Delay Relapse in MRD-Positive AML?
Azacitidine may delay or prevent relapse among patients with MRD-positive acute myeloid leukemia or myelodysplastic syndrome. (Source: CancerNetwork)
Source: CancerNetwork - December 13, 2018 Category: Cancer & Oncology Authors: Bryant Furlow Source Type: news